38 Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs

Side Effects of Drugs Annual

Volumn 29, Issue , 2007, Pages 424-479

  Braun, Felix ^a   Behrend, Matthias ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248682130     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0378-6080(06)29038-X     Document Type: Review

References (350)

1. Agrawal A., Parrott N.R., Riad H.N., and Augustine T. Azathioprine-induced pure red cell aplasia: case report and review. Transplant Proc 36 9 (2004) 2689-2691
2. Depil S., Lepelley P., Soenen V., Preudhomme C., Lai J.L., Broly F., and Quesnel B. A case of refractory anemia with 17p- syndrome following azathioprine treatment for heart transplantation. Leukemia 18 4 (2004) 878
3. Willerding-Mollmann S., Wilkens L., Schlegelberger B., and Kaiser U. Azathioprin-assoziiertes myelodysplastisches Syndrom mit zytogenetischen Aberrationen (Azathioprine-associated myelodysplastic syndrome with cytogenetic aberrations). Dtsch Med Wochenschr 129 22 (2004) 1246-1248
4. Weersma R.K., Peters F.T., Oostenbrug L.E., van den Berg A.P., van Haastert M., Ploeg R.J., Posthumus M.D., Homan van der Heide J.J., Jansen P.L., and van Dullemen H.M. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 20 8 (2004) 843-850
5. Paoluzi O.A., Crispino P., Amantea A., Pica R., Iacopini F., Consolazio A., Di Palma V., Rivera M., and Paoluzi P. Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet's syndrome. Case report and review of literature. Dig Liver Dis 36 5 (2004) 361-366
6. de Jong D.J., Goullet M., and Naber T.H. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol 16 2 (2004) 207-212
7. Sasaki J., Kawamura Y.J., Konishi F., and Tosha T. Colitic cancer developed after introduction of azathioprine. Dig Dis Sci 49 10 (2004) 1727-1729
8. Cohen R.D. Sperm, sex, and 6-MP: the perception on conception. Gastroenterology 127 4 (2004) 1263-1264
9. Norgard B., Pedersen L., Jacobsen J., Rasmussen S.N., and Sorensen H.T. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 19 6 (2004) 679-685
10. Cimaz R., Meregalli E., Biggioggero M., Borghi O., Tincani A., Motta M., Airo P., and Meroni P.L. Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicol Lett 149 1-3 (2004) 155-162
11. Moskovitz D.N., Bodian C., Chapman M.L., Marion J.F., Rubin P.H., Scherl E., and Present D.H. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99 4 (2004) 656-661
12. Sanderson J., Ansari A., Marinaki T., and Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?. Ann Clin Biochem 41 Pt 4 (2004) 294-302
13. Ford L., Prout C., Gaffney D., and Berg J. Whose TPMT activity is it anyway?. Ann Clin Biochem 41 Pt 6 (2004) 498-500
14. Marinaki A.M., Sumi S., Arenas M., Fairbanks L., Harihara S., Shimizu K., Ueta A., and Duley J.A. Allele frequency of inosine triphosphate pyrophosphatase gene polymorphisms in a Japanese population. Nucleosides Nucleotides Nucleic Acids 23 8-9 (2004) 1399-1401
15. Marinaki A.M., Ansari A., Duley J.A., Arenas M., Sumi S., Lewis C.M., Shobowale-Bakre e.-M., Escuredo E., Fairbanks L.D., and Sanderson J.D. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14 3 (2004) 181-187
16. Marinaki A.M., Duley J.A., Arenas M., Ansari A., Sumi S., Lewis C.M., Shobowale-Bakre M., Fairbanks L.D., and Sanderson J. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids 23 8-9 (2004) 1393-1397
17. Gearry R.B., Roberts R.L., Barclay M.L., and Kennedy M.A. Lack of association between the ITPA 94 C → A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14 11 (2004) 779-781
18. Sumi S., Marinaki A.M., Arenas M., Fairbanks L., Shobowale-Bakre M., Rees D.C., Thein S.L., Ansari A., Sanderson J., De Abreu R.A., Simmonds H.A., and Duley J.A. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 111 4-5 (2002) 360-367
19. Rayner C.K., Hart A.L., Hayward C.M., Emmanuel A.V., and Kamm M.A. Azathioprine dose escalation in inflammatory bowel disease. Aliment Pharmacol Ther 20 1 (2004) 65-71
20. Russmann S., and Lauterburg B. Lebensbedrohliche Nebenwirkungen der Gichtbehandlung (Life-threatening adverse effects of pharmacologic antihyperuricemic therapy). Ther Umsch 61 9 (2004) 575-577
21. Seidel W. Panzytopenie unter kombinierter Behandlung mit Azathioprin und Allopurinol (Pancytopenia from combination therapy with azathioprine and allopurinol). Z Rheumatol 63 5 (2004) 425-427
22. Barnes B.H., Borowitz S.M., Saulsbury F.T., Hellems M., and Sutphen J.L. Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J Pediatr Gastroenterol Nutr 38 5 (2004) 509-512
23. Mori H., Yamanaka K., Kaketa M., Tamada K., Hakamada A., Isoda K., Yamanishi K., and Mizutani H. Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis. J Dermatol 31 9 (2004) 731-736
24. Peters T.G., Spinola K.N., West J.C., Aeder M.I., Danovitch G.M., Klintmalm G.B., Gorman K.J., Gordon J.A., Kincaid C.H., and First M.R. Differences in patient and transplant professional perceptions of immunosuppression-induced cosmetic side effects. Transplantation 78 4 (2004) 537-543
25. Campistol J.M., Romero R., Paul J., and Gutierrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant Suppl 3 19 (2004) iii62-iii66
26. Rottenberg Y., and Fridlender Z.G. Recurrent infusion phlebitis induced by cyclosporine. Ann Pharmacother 38 12 (2004) 2071-2073
27. Fortin M.C., Raymond M.A., Madore F., Fugere J.A., Paquet M., St Louis G., and Hebert M.J. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 4 6 (2004) 946-952
28. Choi E.J., Kang J.K., Lee S.A., Kim K.H., Lee S.G., and Andermann F. New-onset seizures after liver transplantation: clinical implications and prognosis in survivors. Eur Neurol 52 4 (2004) 230-236
29. Yu J., Zheng S.S., Liang T.B., Shen Y., Wang W.L., and Ke Q.H. Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol 10 17 (2004) 2540-2543
30. Paul F., Muller J., Christe W., Steinmuller T., Poewe W., and Wissel J. Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy. Clin Transplant 18 4 (2004) 429-433
31. Echaniz-Laguna A., Battaglia F., Ellero B., Mohr M., and Jaeck D. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Muscle Nerve 30 4 (2004) 501-504
32. Borras B.J., Enriquez R., Amoros A.F., Navarro R.A., Conesa G.V., and Gonzalez D.M. Cefalea asociada a ciclosporina en un paciente con glomerulonefritis membranosa (Headache associated with ciclosporine in a patient with membranous glomerulonephritis). Farm Hosp 28 6 (2004) 454-457
33. Buscher R., Vij O., Hudde T., Hoyer P.F., and Vester U. Pseudotumor cerebri following cyclosporine A treatment in a boy with tubulointerstitial nephritis associated with uveitis. Pediatr Nephrol 19 5 (2004) 558-560
34. Marchiori P.E., Mies S., and Scaff M. Cyclosporine A-induced ocular opsoclonus and reversible leukoencephalopathy after orthotopic liver transplantation: brief report. Clin Neuropharmacol 27 4 (2004) 195-197
35. Ciancio G., Burke G.W., Gaynor J.J., Mattiazzi A., Roth D., Kupin W., Nicolas M., Ruiz P., Rosen A., and Miller J. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77 2 (2004) 252-258
36. Tokgoz B., Sari H.I., Yildiz O., Aslan S., Sipahioglu M., Okten T., Oymak O., and Utas C. Effects of azithromycin on cyclosporine-induced gingival hyperplasia in renal transplant patients. Transplant Proc 36 9 (2004) 2699-2702
37. Worm H.C., Wirnsberger G.H., Mauric A., and Holzer H. High prevalence of Chlamydia pneumoniae infection in cyclosporin A-induced post-transplant gingival overgrowth tissue and evidence for the possibility of persistent infection despite short-term treatment with azithromycin. Nephrol Dial Transplant 19 7 (2004) 1890-1894
38. Chen K.J., Chen C.H., Cheng C.H., Wu M.J., and Shu K.H. Risk factors for peptic ulcer disease in renal transplant patients-11 years of experience from a single center. Clin Nephrol 62 1 (2004) 14-20
39. Marr K.A., Hachem R., Papanicolaou G., Somani J., Arduino J.M., Lipka C.J., Ngai A.L., Kartsonis N., Chodakewitz J., and Sable C. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 6 3 (2004) 110-116
40. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Chapman J.R., and Allen R.D. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78 4 (2004) 557-565
41. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Chapman J.R., and Allen R.D. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 78 3 (2004) 434-441
42. Nankivell B.J., Chapman J.R., Bonovas G., and Gruenewald S.M. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 77 9 (2004) 1457-1459
43. Thervet E., Martinez F., and Legendre C. Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients. Drug Saf 27 7 (2004) 457-476
44. Heaphy Jr. M.R., Shamma H.N., Hickmann M., and White M.J. Cyclosporine-induced folliculodystrophy. J Am Acad Dermatol 50 2 (2004) 310-315
45. Courtney A.E., Doherty C., Herron B., McCarron M.O., Connolly J.K., and Jefferson J.A. Acute polymyositis following renal transplantation. Am J Transplant 4 7 (2004) 1204-1207
46. Baildam A.D., Higgins R.M., Hurley E., Furlong A., Walls J., Venning M.C., Ackrill P., and Mansel R.E. Cyclosporin A multiple fibroadenomas of the breast. Br J Surg 83 12 (1996) 1755-1757
47. Alkhunaizi A.M., Ismail A., and Yousif B.M. Breast fibroadenomas in renal transplant recipients. Transplant Proc 36 6 (2004) 1839-1840
48. Kanaan N., and Goffin E. Multiple bilateral fibroadenomas of the breasts requiring mastectomy in a renal transplant patient. Clin Nephrol 61 2 (2004) 151-154
49. Son E.J., Oh K.K., Kim E.K., Cho N., Lee J.D., Kim S.H., and Jung W.H. Characteristic imaging features of breast fibroadenomas in women given cyclosporin A after renal transplantation. J Clin Ultrasound 32 2 (2004) 69-77
50. Dai M.S., Kao W.Y., Shyu R.Y., and Chao T.Y. Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia. J Viral Hepat 11 3 (2004) 283-285
51. Lee Y.A., Kim H.J., Lee T.W., Kim M.J., Lee M.H., Lee J.H., and Ihm C.G. First report of Cryptococcus albidus-induced disseminated cryptococcosis in a renal transplant recipient. Korean J Intern Med 19 1 (2004) 53-57
52. Andre N., Roquelaure B., and Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses 63 4 (2004) 647-652
53. Zavos G., Papaconstantinou I., Chrisostomidis C., and Kostakis A. Metastatic melanoma within a transplanted kidney: a case report. Transplant Proc 36 5 (2004) 1411-1412
54. Ho V.C. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol 150 Suppl 67 (2004) 1-10
55. Lain E.L., and Markus R.F. Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine. J Drugs Dermatol 3 6 (2004) 680-682
56. Ogata M., Kikuchi H., Ono K., Ohtsuka E., Gamachi A., Kashima K., and Nasu M. Spontaneous remission of Epstein-Barr virus-negative non-Hodgkin's lymphoma after withdrawal of cyclosporine in a patient with refractory anemia. Int J Hematol 79 2 (2004) 161-164
57. Dirks N.L., Huth B., Yates C.R., and Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 42 12 (2004) 701-718
58. Tarantino A., Passerini P., Campise M., Bonizzoni E., Ceccarini F., Montagnino G., Aroldi A., and Ponticelli C. Is cyclosporine in renal-transplant recipients more effective when given twice a day than in a single daily dose?. Transplantation 78 5 (2004) 675-680
59. Caforio A.L., Tona F., Piaserico S., Gambino A., Feltrin G., Fortina A.B., Angelini A., Alaibac M., Bontorin M., Calzolari D., Peserico A., Thiene G., Iliceto S., and Gerosa G. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int 18 1 (2005) 116-124
60. Meiser B.M., Groetzner J., Kaczmarek I., Landwehr P., Muller M., Jung S., Uberfuhr P., Fraunberger P., Stempfle H.U., Weis M., and Reichart B. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?. Transplantation 78 4 (2004) 591-598
61. Taylor P.J., Kubler P.A., Lynch S.V., Allen J., Butler M., and Pillans P.I. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 38 2 (2004) 205-208
62. Carcel-Trullols J., Torres-Molina F., Araico A., Saadeddin A., and Peris J.E. Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. Cancer Chemother Pharmacol 54 2 (2004) 153-160
63. Vogel M., Voigt E., Michaelis H.C., Sudhop T., Wolff M., Turler A., Sauerbruch T., Rockstroh J.K., and Spengler U. Management of drug-to-drug interactions between cyclosporine A the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 10 7 (2004) 939-944
64. Innocenti F., Undevia S.D., Ramirez J., Mani S., Schilsky R.L., Vogelzang N.J., Prado M., and Ratain M.J. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther 76 5 (2004) 490-502
65. Wauters J.P., Uehlinger D., and Marti H.P. Drug interaction between sevelamer and cyclosporin. Nephrol Dial Transplant 19 7 (2004) 1939-1940
66. Guillen-Anaya M.A., and Jadoul M. Drug interaction between sevelamer and cyclosporin. Nephrol Dial Transplant 19 2 (2004) 515
67. Pieper A.K., Buhle F., Bauer S., Mai I., Budde K., Haffner D., Neumayer H.H., and Querfeld U. The effect of sevelamer on the pharmacokinetics of cyclosporin A mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant 19 10 (2004) 2630-2633
68. Izzo A.A. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 42 3 (2004) 139-148
69. Mai I., Bauer S., Perloff E.S., Johne A., Uehleke B., Frank B., Budde K., and Roots I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 76 4 (2004) 330-340
70. Knuppel L., and Linde K. Adverse effects of St. John's wort: a systematic review. J Clin Psychiatry 65 11 (2004) 1470-1479
71. Groll A.H., Kolve H., Ehlert K., Paulussen M., and Vormoor J. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother 53 1 (2004) 113-114
72. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., and Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 350 10 (2004) 971-980
73. Chapman T.M., and Perry C.M. Everolimus. Drugs 64 8 (2004) 861-872
74. Budde K., Neumayer H.H., Lehne G., Winkler M., Hauser I.A., Lison A., Fritsche L., Soulillou J.P., Fauchald P., Dantal J., and RADW 102 Renal Transplant Study Group. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant 19 10 (2004) 2606-2614
75. Vitko S., Margreiter R., Weimar W., Dantal J., Viljoen H.G., Li Y., Jappe A., Cretin N., and RAD B201 Study Group. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78 10 (2004) 1532-1540
76. Deters M., Kirchner G., Koal T., Resch K., and Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci 49 1 (2004) 30-37
77. Dorschner L., Speich R., Ruschitzka F., Seebach J.D., and Gallino A. Everolimus-induced drug fever after heart transplantation. Transplantation 78 2 (2004) 303-304
78. Nashan B., Curtis J., Ponticelli C., Mourad G., Jaffe J., and Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78 9 (2004) 1332-1340
79. Kirchner G.I., Meier-Wiedenbach I., and Manns M.P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43 2 (2004) 83-95
80. Kunzendorf U., Ziegler E., and Kabelitz D. FTY720-the first compound of a new promising class of immunosuppressive drugs. Nephrol Dial Transplant 19 7 (2004) 1677-1681
81. Tedesco-Silva H., Mourad G., Kahan B.D., Boira J.G., Weimar W., Mulgaonkar S., Nashan B., Madsen S., Charpentier B., Pellet P., and Vanrenterghem Y. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 77 12 (2004) 1826-1833 Corrected and republished in:
82. Tedesco-Silva H., Mourad G., Kahan B.D., Boira J.G., Weimar W., Mulgaonkar S., Nashan B., Madsen S., Charpentier B., Pellet P., and Vanrenterghem Y. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 79 11 (2005) 1553-1560
83. Kovarik J.M., Schmouder R.L., Barilla D., Buche M., Rouilly M., Berthier S., Wang Y., Van Saders C., Mayer T., and Gottlieb A.B. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. Ann Pharmacother 38 7-8 (2004) 1153-1158
84. Arnon R., and Sela M. Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit 16 6 (2003) 412-421
85. Munari L., Lovati R., and Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 1 (2004) CD004678
86. Soos N., Shakery K., and Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol 5 5 (2004) 357-359
87. Ferrero S., Pretta S., and Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 115 1 (2004) 3-9
88. Bartlett R.R., and Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity-I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 7 1 (1985) 7-18
89. Imose M., Nagaki M., Kimura K., Takai S., Imao M., Naiki T., Osawa Y., Asano T., Hayashi H., and Moriwaki H. Leflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor kappaB. Hepatology 40 5 (2004) 1160-1169
90. Manna S.K., Mukhopadhyay A., and Aggarwal B.B. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 165 10 (2000) 5962-5969
91. Manna S.K., and Aggarwal B.B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 162 4 (1999) 2095-2102
92. Breedveld F.C., and Dayer J.M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59 11 (2000) 841-849
93. Kremer J.M. What I would like to know about leflunomide. J Rheumatol 31 6 (2004) 1029-1031
94. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 41 6 (2002) 421-430
95. Kaltwasser J.P., and Behrens F. Leflunomide: long-term clinical experience and new uses. Expert Opin Pharmacother 6 5 (2005) 787-801
96. Mladenovic V., Domljan Z., Rozman B., Jajic I., Mihajlovic D., Dordevic J., Popovic M., Dimitrijevic M., Zivkovic M., Campion G., et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 38 11 (1995) 1595-1603
97. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., Fox R., Moreland L., Olsen N., Furst D., Caldwell J., Kaine J., Sharp J., Hurley F., Loew-Friedrich I., and Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 159 21 (1999) 2542-2550
98. Smolen J.S., Kalden J.R., Scott D.L., Rozman B., Kvien T.K., Larsen A., Loew-Friedrich I., Oed C., Rosenburg R., and European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353 9149 (1999) 259-266
99. Smolen J.S. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol Suppl 112 (1999) 15-21
100. Emery P., Breedveld F.C., Lemmel E.M., Kaltwasser J.P., Dawes P.T., Gomor B., Van Den Bosch F., Nordstrom D., Bjorneboe O., Dahl R., Horslev-Petersen K., Rodriguez De La Serna A., Molloy M., Tikly M., Oed C., Rosenburg R., and Loew-Friedrich I. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39 6 (2000) 655-665
101. Larsen A., Kvien T.K., Schattenkirchner M., Rau R., Scott D.L., Smolen J.S., Rozman B., Westhovens R., Tikly M., Oed C., Rosenburg R., and European Leflunomide Study Group. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 30 3 (2001) 135-142
102. Cohen S., Cannon G.W., Schiff M., Weaver A., Fox R., Olsen N., Furst D., Sharp J., Moreland L., Caldwell J., Kaine J., Strand V., and Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 44 9 (2001) 1984-1992
103. Scott D.L., Smolen J.S., Kalden J.R., van de Putte L.B., Larsen A., Kvien T.K., Schattenkirchner M., Nash P., Oed C., Loew-Friedrich I., and European Leflunomide Study Group. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 60 10 (2001) 913-923
104. Kiely P.D., and Johnson D.M. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) 41 6 (2002) 631-637
105. Kremer J.M., Genovese M.C., Cannon G.W., Caldwell J.R., Cush J.J., Furst D.E., Luggen M.E., Keystone E., Weisman M.H., Bensen W.M., Kaine J.L., Ruderman E.M., Coleman P., Curtis D.L., Kopp E.J., Kantor S.M., Waltuck J., Lindsley H.B., Markenson J.A., Strand V., Crawford B., Fernando I., Simpson K., and Bathon J.M. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137 9 (2002) 726-733
106. Kalden J.R., Schattenkirchner M., Sorensen H., Emery P., Deighton C., Rozman B., and Breedveld F. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 48 6 (2003) 1513-1520
107. Dougados M., Emery P., Lemmel E.M., De la Serna R., Zerbini C.A., Brin S., and Van Riel P. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 30 12 (2003) 2572-2579
108. Godinho F., Godfrin B., El Mahou S., Navaux F., Zabraniecki L., and Cantagrel A. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol 22 3 (2004) 328-330
109. Jaimes-Hernandez J., Robles-San Roman M., Suarez-Otero R., Davalos-Zugasti M.E., and Arroyo-Borrego S. Rheumatoid arthritis treatment with weekly leflunomide: an open-label study. J Rheumatol 31 2 (2004) 235-237
110. Nyugen M., Kabir M., and Ravaud P. Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use. Clin Drug Invest 24 2 (2004) 103-112
111. Kremer J., Genovese M., Cannon G.W., Caldwell J., Cush J., Furst D.E., Luggen M., Keystone E., Bathon J., Kavanaugh A., Ruderman E., Coleman P., Curtis D., Kopp E., Kantor S., Weisman M., Waltuck J., Lindsley H.B., Markenson J., Crawford B., Fernando I., Simpson K., and Strand V. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 31 8 (2004) 1521-1531
112. Poor G., and Strand V. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. Rheumatology (Oxford) 43 6 (2004) 744-749
113. Van Roon E.N., Jansen T.L., Mourad L., Houtman P.M., Bruyn G.A., Griep E.N., Wilffert B., Tobi H., and Brouwers J.R. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 58 2 (2004) 201-208
114. Li E.K., Tam L.S., and Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 26 4 (2004) 447-459
115. Osiri M., Shea B., Robinson V., Suarez-Almazor M., Strand V., Tugwell P., and Wells G. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 30 6 (2003) 1182-1190
116. Maddison P., Kiely P., Kirkham B., Lawson T., Moots R., Proudfoot D., Reece R., Scott D., Sword R., Taggart A., Thwaites C., and Williams E. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 44 3 (2005) 280-286
117. Prajapati D.N., Knox J.F., Emmons J., Saeian K., Csuka M.E., and Binion D.G. Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 37 2 (2003) 125-128
118. Kaltwasser J.P., Nash P., Gladman D., Rosen C.F., Behrens F., Jones P., Wollenhaupt J., Falk F.G., Mease P., and Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50 6 (2004) 1939-1950
119. Tlacuilo-Parra J.A., Guevara-Gutierrez E., Rodriguez-Castellanos M.A., Ornelas-Aguirre J.M., Barba-Gomez J.F., and Salazar-Paramo M. Leflunomide in the treatment of psoriasis: results of a phase II open trial. Br J Dermatol 150 5 (2004) 970-976
120. Baughman R.P., and Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 21 1 (2004) 43-48
121. Tam L.S., Li E.K., Wong C.K., Lam C.W., and Szeto C.C. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13 8 (2004) 601-604
122. Metzler C., Fink C., Lamprecht P., Gross W.L., and Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43 3 (2004) 315-320
123. Williams J.W., Mital D., Chong A., Kottayil A., Millis M., Longstreth J., Huang W., Brady L., and Jensik S. Experiences with leflunomide in solid organ transplantation. Transplantation 73 3 (2002) 358-366
124. Hardinger K.L., Wang C.D., Schnitzler M.A., Miller B.W., Jendrisak M.D., Shenoy S., Lowell J.A., and Brennan D.C. Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2 9 (2002) 867-871
125. John G.T., Manivannan J., Chandy S., Peter S., and Jacob C.K. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 77 9 (2004) 1460-1461
126. Schlapfer E., Fischer M., Ott P., and Speck R.F. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS 17 11 (2003) 1613-1620
127. Kelly L.M., Lisziewicz J., and Lori F. "Virostatics" as a potential new class of HIV drugs. Curr Pharm Des 10 32 (2004) 4103-4120
128. Hewitson P.J., Debroe S., McBride A., and Milne R. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J Clin Pharm Ther 25 4 (2000) 295-302
129. Van Riel P.L., Smolen J.S., Emery P., Kalden J.R., Dougados M., Strand C.V., and Breedveld F.C. Leflunomide: a manageable safety profile. J Rheumatol Suppl 71 (2004) 21-24
130. Hoi A., and Littlejohn G.O. Aminotransferase levels during treatment of rheumatoid arthritis with leflunomide in clinical practice. Ann Rheum Dis 62 4 (2003) 379
131. Coblyn J.S., Shadick N., and Helfgott S. Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis Rheum 44 5 (2001) 1048-1051
132. Laborde F., Loeuille D., and Chary-Valckenaere I. Life-threatening hypertriglyceridemia during leflunomide therapy in a patient with rheumatoid arthritis. Arthritis Rheum 50 10 (2004) 3398
133. Macdonald J., Zhong T., Lazarescu A., Gan B.S., and Harth M. Vasculitis associated with the use of leflunomide. J Rheumatol 31 10 (2004) 2076-2078
134. Cohen J.D., Jorgensen C., and Sany J. Leflunomide-induced aseptic meningitis. Joint Bone Spine 71 3 (2004) 243-245
135. Carulli M.T., and Davies U.M. Peripheral neuropathy: an unwanted effect of leflunomide?. Rheumatology (Oxford) 41 8 (2002) 952-953
136. Siva C., Eisen S.A., Shepherd R., Cunningham F., Fang M.A., Finch W., Salisbury D., Singh J.A., Stern R., and Zarabadi S.A. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum 49 6 (2003) 745-751
137. Cannon G.W., Holden W.L., Juhaeri J., Dai W., Scarazzini L., and Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD) (2004) a cohort study of leflunomide compared with other DMARD. J Rheumatol 31 10 (2004) 1906-1911
138. Rozman B., and Leflunomide Investigators' Group. Clinical experience with leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53 (1998) 27-32
139. Rozman B., Praprotnik S., Logar D., Tomsic M., Hojnik M., Kos-Golja M., Accetto R., and Dolenc P. Leflunomide and hypertension. Ann Rheum Dis 61 6 (2002) 567-569
140. Martinez-Taboada V.M., Rodriguez-Valverde V., Gonzalez-Vilchez F., and Armijo J.A. Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide. Rheumatology (Oxford) 43 11 (2004) 1451-1453
141. Takeishi M., Akiyama Y., Akiba H., Adachi D., Hirano M., and Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol 32 6 (2005) 1160-1163
142. Kamata Y., Nara H., Kamimura T., Haneda K., Iwamoto M., Masuyama J., Okazaki H., and Minota S. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43 12 (2004) 1201-1204
143. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 363 9407 (2004) 461
144. Ito S., and Sumida T. Interstitial lung disease associated with leflunomide. Intern Med 43 12 (2004) 1103-1104
145. Scott D.L. Interstitial lung disease and disease modifying anti-rheumatic drugs. Lancet 363 9416 (2004) 1239-1240
146. Ulusoy H., Bilgici A., Kuru O., and Celenk C. Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report. Rheumatol Int 25 2 (2005) 139-142
147. Kopp H.G., Kanz L., Hartmann J.T., and Moerike K. Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide. Clin Pharmacol Ther 78 1 (2005) 89-90
148. Bharadwaj A., and Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 43 7 (2004) 934
149. Bonnel R.A., and Graham D.J. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 75 6 (2004) 580-585
150. Martin K., Bentaberry F., Dumoulin C., Longy-Boursier M., Lifermann F., Haramburu F., Dehais J., Schaeverbeke T., Begaud B., and Moore N. Neuropathy associated with leflunomide: a case series. Ann Rheum Dis 64 4 (2005) 649-650
151. Barak A., Morse L.S., and Schwab I. Leflunomide (Arava)-induced cystoid macular oedema. Rheumatology (Oxford) 43 2 (2004) 246-248
152. Chan J., Sanders D.C., Du L., and Pillans P.I. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 38 7-8 (2004) 1206-1211
153. Hill R.L., Topliss D.J., and Purcell P.M. Pancytopenia associated with leflunomide and methotrexate. Ann Pharmacother 37 1 (2003) 149
154. Auer J., Hinterreiter M., Allinger S., Kirchgatterer A., and Knoflach P. Severe pancytopenia after leflunomide in rheumatoid arthritis. Acta Med Austriaca 27 4 (2000) 131-132
155. Koenig A.S., and Abruzzo J.L. Leflunomide induced fevers, thrombocytosis, and leukocytosis in a patient with relapsing polychondritis. J Rheumatol 29 1 (2002) 192-194
156. Verschueren P., Vandooren A.K., and Westhovens R. Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. Clin Rheumatol 24 1 (2005) 87-90
157. Cannon G.W., and Kremer J.M. Leflunomide. Rheum Dis Clin North Am 30 2 (2004) 295-309 vi
158. Suissa S., Ernst P., Hudson M., Bitton A., and Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 117 2 (2004) 87-92
159. Van Roon E.N., Jansen T.L., Houtman N.M., Spoelstra P., and Brouwers J.R. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 27 5 (2004) 345-352
160. Gao J.S., Wu H., and Tian J. Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate. Zhonghua Er Ke Za Zhi 41 6 (2003) 435-438
161. Schiemann U., and Kellner H. Gastrointestinale Nebenwirkungen der Therapie rheumatischer Erkrankungen. Z Gastroenterol 40 11 (2002) 937-943
162. Anonymous. Severe liver damage with leflunomide. Prescrire Int 10 55 (2001) 149
163. Sevilla-Mantilla C., Ortega L., Agundez J.A., Fernandez-Gutierrez B., Ladero J.M., and Diaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis 36 1 (2004) 82-84
164. Thomasset S.C., Ong S.L., and Large S.R. Post-coronary artery bypass graft liver failure: a possible association with leflunomide. Ann Thorac Surg 79 2 (2005) 698-699
165. Moynihan R. FDA officials argue over safety of new arthritis drug. Br Med J 326 7389 (2003) 565
166. Aventis Pharmaceuticals Inc. Arava Tablets (leflunomide) 10 mg, 20 mg, 100 mg. Product information, 2005
167. Haydar A.A., Hujairi N., Kirkham B., Hangartner R., and Goldsmith D.J. Chronic overdose of leflunomide inducing interstitial nephritis. Nephrol Dial Transplant 19 5 (2004) 1334-1335
168. Fischer T.W., Bauer H.I., Graefe T., Barta U., and Elsner P. Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology 207 4 (2003) 386-389
169. Bandyopadhyay D. Exfoliative dermatitis induced by leflunomide therapy. J Dermatol 30 11 (2003) 845-846
170. Canonne-Courivaud D., Carpentier O., Dejobert Y., Hachulla E., and Delaporte E. Toxidermie lichenoide au leflunomide (Arava). Dermatol Venereol 130 4 (2003) 435-437
171. McCoy C.M. Leflunomide-associated skin ulceration. Ann Pharmacother 36 6 (2002) 1009-1011
172. Rivarola de Gutierrez E., and Abaca H. Photodistributed lichenoid drug eruption with rhabdomyolysis occurring during leflunomide therapy. Dermatology 208 3 (2004) 232-233
173. Kerr O.A., Murray C.S., and Tidman M.J. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol 29 3 (2004) 319-320
174. Chan A.T., Bradlow A., and McNally J. Leflunomide induced vasculitis-a dose-response relationship. Rheumatology (Oxf) 42 3 (2003) 492-493
175. Holm E.A., Balslev E., and Jemec G.B. Vasculitis occurring during leflunomide therapy. Dermatology 203 3 (2001) 258-259
176. Brent R.L. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63 2 (2001) 106-112
177. De Santis M., Straface G., Cavaliere A., Carducci B., and Caruso A. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 64 7 (2005) 1096-1097
178. Brent R.L. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents). Pediatrics 113 Suppl 4 (2004) 984-995
179. Kaplan M.J. Leflunomide Aventis Pharma. Curr Opin Investig Drugs 2 2 (2001) 222-230
180. Ostensen M. Disease specific problems related to drug therapy in pregnancy. Lupus 13 9 (2004) 746-750
181. Jakez-Ocampo J., Richaud-Patin Y., Granados J., Sanchez-Guerrero J., and Llorente L. Weekly leflunomide as monotherapy for recent-onset rheumatoid arthritis. Arthritis Rheum 51 1 (2004) 147-148
182. Kamali S., Kasapoglu E., Uysal M., Inanc M., and Gul A. An unusual overdose of leflunomide in a patient with rheumatoid arthritis. Ann Pharmacother 38 7-8 (2004) 1320-1321
183. Flendrie M., Creemers M.C., Welsing P.M., and van Riel P.L. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford) 44 4 (2005) 472-478
184. Hansen K.E., Cush J., Singhal A., Cooley D.A., Cohen S., Patel S.R., Genovese M., Sundaramurthy S., and Schiff M. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 51 2 (2004) 228-232
185. Kale V.P., and Bichile L.S. Leflunomide: a novel disease modifying anti-rheumatic drug. J Postgrad Med 50 2 (2004) 154-157
186. Lim V., and Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. Br Med J 325 7376 (2002) 1333
187. Rettie A.E., and Jones J.P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45 (2005) 477-494
188. Chan V., Charles B.G., and Tett S.E. Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 803 2 (2004) 331-335
189. Schmidt A., Schwind B., Gillich M., Brune K., and Hinz B. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography. Biomed Chromatogr 17 4 (2003) 276-281
190. Fitzsimmons W.E., and First M.R. FK778, a synthetic malononitrilamide. Yonsei Med J 45 6 (2004) 1132-1135
191. Vanrenterghem Y., van Hooff J.P., Klinger M., Wlodarczyk Z., Squifflet J.P., Mourad G., Neuhaus P., Jurewicz A., Rostaing L., Charpentier B., Paczek L., Kreis H., Chang R., Paul L.C., Grinyo J.M., and Short C. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 78 1 (2004) 9-14
192. Longhi A., Pasini E., Bertoni F., Pignotti E., Ferrari C., and Bacci G. Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy. J Chemother 16 6 (2004) 582-588
193. Taub J.W., and Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 44 1 (2005) 33-39
194. Moore T.J., Walsh C.S., and Cohen M.R. Reported medication errors associated with methotrexate. Am J Health Syst Pharm 61 13 (2004) 1380-1384
195. Breedveld P., Zelcer N., Pluim D., Sonmezer O., Tibben M.M., Beijnen J.H., Schinkel A.H., van Tellingen O., Borst P., and Schellens J.H. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64 16 (2004) 5804-5811
196. Hempel G., Lingg R., and Boos J. Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol 55 4 (2005) 347-353
197. Bartha P., Bron R., and Levy Y. Fatal pancytopenia and methotrexate-trimethoprim-sulfamethoxazole interaction. Harefuah 143 6 (2004) 398-400 464
198. Zhou H., Mayer P.R., Wajdula J., and Fatenejad S. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 44 11 (2004) 1235-1243
199. Uwai Y., Taniguchi R., Motohashi H., Saito H., Okuda M., and Inui K. Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet 19 5 (2004) 369-374
200. Hartmann S.N., Rordorf C.M., Milosavljev S., Branson J.M., Chales G.H., Juvin R.R., Lafforgue P., Le Parc J.M., Tavernier C.G., and Meyer O.C. Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Ann Pharmacother 38 10 (2004) 1582-1587
201. Jansen G., van der H.J., Oerlemans R., Lems W.F., Ifergan I., Scheper R.J., Assaraf Y.G., and Dijkmans B.A. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 50 7 (2004) 2130-2139
202. Tanaka H., Abe T., Nishimura S., Sakai H., Kimura H., Oki M., Nojima M., Taga M., Matsumoto S., Takahashi H., and Imai K. A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy. Nihon Rinsho Meneki Gakkai Kaishi 27 3 (2004) 171-176
203. McCaughan G. Molecular approaches to the side effects of immunosuppressive drugs. Transplantation 78 8 (2004) 1114-1115
204. Renders L., Steinbach R., Valerius T., Schocklmann H.O., and Kunzendorf U. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 27 3 (2004) 181-185
205. Delgado S., and Duran M.I. Encefalitis en paciente transplantado renal (Encephalitis in a renal transplantation patient). Nefrologia 24 Suppl 3 (2004) 21-25
206. Waldman M.A., and Callen J.P. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol 51 Suppl 2 (2004) S124-S130
207. Vanrenterghem Y. Anaemia after renal transplantation. Nephrol Dial Transplant 19 Suppl 5 (2004) V54-V58
208. Apostolou T., Tsagalis G., Koutroubas G., Hadjiconstantinou V., and Drakopoulos S. Mycophenolate mofetil and oral ulcerations. Transplantation 77 12 (2004) 1911-1912
209. Kamar N., Faure P., Dupuis E., Cointault O., Joseph-Hein K., Durand D., Moreau J., and Rostaing L. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int 17 8 (2004) 463-467
210. Brunt E.M., and Di Bisceglie A.M. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. Hum Pathol 35 4 (2004) 509-512
211. Piccoli G.B., Rossetti M., Guarena C., Consiglio V., Mezza E., Soragna G., Grassi G., Burdese M., Gai M., Marchetti P., Boggi U., and Segoloni G.P. Myalgia: an uncommon or underestimated side effect of mycophenolate mophetil after transplantation?. Nephrol Dial Transplant 19 7 (2004) 1940-1942
212. Gourishankar S., McDermid J.C., Jhangri G.S., and Preiksaitis J.K. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 4 1 (2004) 108-115
213. Zekry A., Gleeson M., Guney S., and McCaughan G.W. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 10 1 (2004) 52-57
214. Tarner I.H., Schneidewind A., Linde H.J., Schubert T., Scholmerich J., Gluck T., and Müller-Ladner U. Maxillary actinomycosis in an immunocompromised patient with longstanding vasculitis treated with mycophenolate mofetil. J Rheumatol 31 9 (2004) 1869-1871
215. Le Ray C., Coulomb A., Elefant E., Frydman R., and Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103 5 Pt 2 (2004) 1091-1094
216. Mudge D.W., Atcheson B.A., Taylor P.J., Pillans P.I., and Johnson D.W. Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit 26 4 (2004) 453-455
217. Budde K., Glander P., Diekmann F., Waiser J., Fritsche L., Dragun D., and Neumayer H.H. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 5 6 (2004) 1333-1345
218. Masri M.A., Andrysek T., Rizk S., and Matha V. The role of generics in transplantation: TM-MMF versus Cellcept in healthy volunteers. Transplant Proc 36 1 (2004) 84-85
219. Bebarta V.S., Heard K., and Nadelson C. Lack of toxic effects following acute overdose of cellcept (mycophenolate mofetil). J Toxicol Clin Toxicol 42 6 (2004) 917-919
220. Gimenez F., Foeillet E., Bourdon O., Weller S., Garret C., Bidault R., and Singlas E. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet 43 10 (2004) 685-692
221. Sankatsing S.U., Hoggard P.G., Huitema A.D., Sparidans R.W., Kewn S., Crommentuyn K.M., Lange J.M., Beijnen J.H., Back D.J., and Prins J.M. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet 43 12 (2004) 823-832
222. Orenz M., Wolzt M., Weigel G., Puttinger H., Horl W.H., Fodinger M., Speiser W., and Sunder-Plassmann G. Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. Am J Kidney Dis 43 6 (2004) 1098-1103
223. Mudge D.W., Atcheson B., Taylor P.J., Sturtevant J.M., Hawley C.M., Campbell S.B., Isbel N.M., Nicol D.L., Pillans P.I., and Johnson D.W. The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation 77 2 (2004) 206-209
224. Kuypers D.R., Claes K., Evenepoel P., Maes B., and Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 75 5 (2004) 434-447
225. Tredger J.M., Brown N.W., Adams J., Gonde C.E., Dhawan A., Rela M., and Heaton N. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 10 4 (2004) 492-502
226. Atcheson B.A., Taylor P.J., Kirkpatrick C.M., Duffull S.B., Mudge D.W., Pillans P.I., Johnson D.W., and Tett S.E. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 26 3 (2004) 284-286
227. Filler G., and Lepage N. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Pediatr Nephrol 19 9 (2004) 962-965
228. Dauden E., Sanchez-Peinado C., Ruiz-Genao D., Garcia F.V., Onate M.J., and Garcia-Diez A. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. Br J Dermatol 150 1 (2004) 132-135
229. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis. Prescrire Int 13 74 (2004) 209-212
230. Luger T.A., Lahfa M., Folster-Holst R., Gulliver W.P., Allen R., Molloy S., Barbier N., Paul C., and Bos J.D. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 15 3 (2004) 169-178
231. Crawford K.M., Bostrom P., Russ B., and Boyd J. Pimecrolimus-induced tinea incognito. Skinmed 3 6 (2004) 352-353
232. Anonymous. Pimecrolimus/tacrolimus. Potential cancer risk. WHO Pharmaceutical Newslett 2 (2005) 3-4
233. Kahan B.D. Sirolimus-based immunosuppression: present state of the art. J Nephrol 17 Suppl 8 (2004) S32-S39
234. Golling M., Becker T., Broelsch C., Candinas D., Faust D., Fischer L., Geissler E., Graeb C., Iberer F., Klupp J., Kraus T., Muller A.R., Neuhaus P., Strassburg C.P., Wolff M., Zulke C., and Bechstein W.O. Konsensusempfehlung zum Einsatz von Sirolimus in der Lebertransplantation (Consensus-recommendations for sirolimus in liver transplantation). Z Gastroenterol 42 11 (2004) 1333-1340
235. Kneteman N.M., Oberholzer J., Al Saghier M., Meeberg G.A., Blitz M., Ma M.M., Wong W.W., Gutfreund K., Mason A.L., Jewell L.D., Shapiro A.M., Bain V.G., and Bigam D.L. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10 10 (2004) 1301-1311
236. Montalbano M., Neff G.W., Yamashiki N., Meyer D., Bettiol M., Slapak-Green G., Ruiz P., Manten E., Safdar K., O'Brien C., and Tzakis A.G. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 78 2 (2004) 264-268
237. Paramesh A.S., Grosskreutz C., Florman S.S., Gondolesi G.E., Sharma S., Kaufman S.S., and Fishbein T.M. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 77 1 (2004) 129-131
238. Pham P.T., Pham P.C., Danovitch G.M., Ross D.J., Gritsch H.A., Kendrick E.A., Singer J., Shah T., and Wilkinson A.H. Sirolimus-associated pulmonary toxicity. Transplantation 77 8 (2004) 1215-1220
239. Vlahakis N.E., Rickman O.B., and Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 79 4 (2004) 541-545
240. Haydar A.A., Denton M., West A., Rees J., and Goldsmith D.J. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 4 1 (2004) 137-139
241. Shefet D., Ben Dor I., and Lustig S. Sirolimus-induced interstitial pneumonitis after renal transplantation. Transplantation 78 6 (2004) 950
242. Martinez M., Gonzalez Roncero F.M., Lopez M., Toro J., Valdivia M.A., Pereira P., Gentil M.A., Rodriguez Algarra G., and Mateos J. Neumonitis intersticial asociada al uso de sirolimus en un transplantado renal un caso clinico (Interstitial pneumonitis associated with sirolimus administration in a renal transplantation patient: a clinical case). Nefrologia 24 Suppl 3 (2004) 7-10
243. Lee C.Y., Tsai M.K., and Lee P.H. Difficulty in establishing sirolimus therapy as a cause of interstitial pneumonitis in renal-transplant recipients. J Formos Med Assoc 103 9 (2004) 731-732
244. Manito N., Kaplinsky E.J., Bernat R., Roca J., Castells E., Serrano T., and Esplugas E. Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant 23 6 (2004) 780-782
245. Groetzner J., Kur F., Spelsberg F., Behr J., Frey L., Bittmann I., Vogeser M., Ueberfuhr P., Meiser B., Hatz R., Reichart B., and Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 23 5 (2004) 632-638
246. Kaczmarek I., Groetzner J., Adamidis I., Landwehr P., Mueller M., Vogeser M., Gerstorfer M., Uberfuhr P., Meiser B., and Reichart B. Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 4 7 (2004) 1084-1088
247. Firpi R.J., Tran T.T., Flores P., Nissen N., Colquhoun S., Shackleton C., Martin P., Vierling J.M., and Poordad F.F. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment Pharmacol Ther 19 9 (2004) 1033-1039
248. Kniepeiss D., Iberer F., Schaffellner S., Jakoby E., Duller D., and Tscheliessnigg K. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 18 6 (2004) 642-646
249. Mathis A.S., Dave N., Knipp G.T., and Friedman G.S. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 61 6 (2004) 565-585
250. Augustine J.J., Knauss T.C., Schulak J.A., Bodziak K.A., Siegel C., and Hricik D.E. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 4 12 (2004) 2001-2006
251. Aboujaoude W., Milgrom M.L., and Govani M.V. Lymphedema associated with sirolimus in renal transplant recipients. Transplantation 77 7 (2004) 1094-1096
252. Neff G.W., Ruiz P., Madariaga J.R., Nishida S., Montalbano M., Meyer D., Levi D.M., Tzakis A.G., and O'Brien C.B. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 38 10 (2004) 1593-1596
253. Fervenza F.C., Fitzpatrick P.M., Mertz J., Erickson S.B., Liggett S., Popham S., Wochos D.N., Synhavsky A., Hippler S., Larson T.S., Bagniewski S.M., Velosa J.A., and Mayo Nephrology Collaborative Committee. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 19 5 (2004) 1288-1292
254. Dittrich E., Schmaldienst S., Soleiman A., Horl W.H., and Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 17 4 (2004) 215-220
255. Rampino T., Marasa M., Malvezzi P.M., Soccio G., Roscini E., Gamba G., Noris P., Alessiani M., and Dal Canton A. Platelet-Independent defect in hemostasis associated with sirolimus use. Transplant Proc 36 3 (2004) 700-702
256. Wadei H., Gruber S.A., El-Amm J.M., Garnick J., West M.S., Granger D.K., Sillix D.H., Migdal S.D., and Haririan A. Sirolimus-induced angioedema. Am J Transplant 4 6 (2004) 1002-1005
257. Fisher A., Seguel J.M., de la Torre A.N., Wilson D., Merchant A., Arora R.K., and Koneru B. Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl 10 2 (2004) 193-198
258. Dean P.G., Lund W.J., Larson T.S., Prieto M., Nyberg S.L., Ishitani M.B., Kremers W.K., and Stegall M.D. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77 10 (2004) 1555-1561
259. Lo A., Egidi M.F., Gaber L.W., Shokouh-Amiri M.H., Nazakatgoo N., Fisher J.S., and Gaber O. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 18 1 (2004) 53-61
260. Zimmerman J.J. Exposure-response relationships and drug interactions of sirolimus. AAPS J 6 4 (2004) e28
261. Sadaba B., Campanero M.A., Quetglas E.G., and Azanza J.R. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 36 10 (2004) 3226-3228
262. Mathis A.S., Shah N.K., and Friedman G.S. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 36 9 (2004) 2708-2709
263. Cattaneo D., Merlini S., Pellegrino M., Carrara F., Zenoni S., Murgia S., Baldelli S., Gaspari F., Remuzzi G., and Perico N. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 4 8 (2004) 1345-1351
264. First M.R. Tacrolimus based immunosuppression. J Nephrol 17 Suppl 8 (2004) S25-S31
265. Baid-Agrawal S., Delmonico F.L., Tolkoff-Rubin N.E., Farrell M., Williams W.W., Shih V., Auchincloss H., Cosimi A.B., and Pascual M. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 77 8 (2004) 1199-1202
266. Gutierrez dlF., Sola E., Alferez M.J., Navarro A., Cabello M., Burgos D., and Gonzalez Molina M. Sindrome emolitico urémico de novo en el postoperatorio de un transplante renopancreatico (De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period). Nefrologia 24 Suppl 3 (2004) 3-6
267. Kohli-Seth R., Killu C., Amolat M.J., Oropello J., Manasia A., Leibowitz A., Bassily-Marcus A., and Benjamin E. Bronchiolitis obliterans organizing pneumonia after orthotopic liver transplantation. Liver Transpl 10 3 (2004) 456-459
268. Lacaille F., Hertz-Pannier L., and Nassogne M.C. Magnetic resonance imaging for the diagnosis of acute leukoencephalopathy in children treated with tacrolimus. Neuropediatrics 35 2 (2004) 130-133
269. Tamaki H., Kawakami M., Ikegame K., Iio K., Harada Y., Hatanaka K., Oka Y., Kawase I., and Ogawa H. Successful treatment of tacrolimus (FK506)-related leukoencephalopathy with cerebral hemorrhage in a patient who underwent nonmyeloablative stem cell transplantation. Int J Hematol 80 3 (2004) 291-294
270. Ohta K., Yoritaka A., Sakamaki H., and Kishida S. Immunosuppressive-associated encephalopathy in bone marrow transplant recipients. No To Shinkei 56 5 (2004) 395-401
271. Lai M.M., Kerrison J.B., and Miller N.R. Reversible bilateral internuclear ophthalmoplegia associated with FK506. J Neurol Neurosurg Psychiatry 75 5 (2004) 776-778
272. Heisel O., Heisel R., Balshaw R., and Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4 4 (2004) 583-595
273. Gourishankar S., Jhangri G.S., Tonelli M., Wales L.H., and Cockfield S.M. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 4 11 (2004) 1876-1882
274. Gerster J.C., Dudler M., Halkic N., and Gillet M. Gout in liver transplant patients receiving tacrolimus. Ann Rheum Dis 63 7 (2004) 894-895
275. Higgins R., Ramaiyan K., Dasgupta T., Kanji H., Fletcher S., Lam F., and Kashi H. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transplant 19 2 (2004) 444-450
276. Kausman J.Y., Powell H.R., and Jones C.L. Anemia in pediatric renal transplant recipients. Pediatr Nephrol 19 5 (2004) 526-530
277. Nosari A., Marbello L., De Carlis L.G., De Gasperi A., Muti G., Mancini V., and Morra E. Bone marrow hypoplasia complicating tacrolimus (FK506) therapy. Int J Hematol 79 2 (2004) 130-132
278. Asano T., Nishimoto K., and Hayakawa M. Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant Proc 36 7 (2004) 2096-2097
279. Miyagawa-Hayashino A., Haga H., Egawa H., Hayashino Y., Sakurai T., Minamiguchi S., Tanaka K., and Manabe T. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 78 1 (2004) 128-135
280. Antonini M., Ettorre G.M., Vennarecci G., D'Offizi G., Narciso P., Del Nonno F., Perracchio L., Visco G., and Santoro E. Anti-retrovirals and immunosuppressive drug interactions in a HIV-positive patient after liver transplantation. Hepatogastroenterology 51 57 (2004) 646-648
281. Neuberger J., Gunson B., Hubscher S., and Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 10 4 (2004) 488-491
282. Nieto Y., Russ P., Everson G., Bearman S.I., Cagnoni P.J., Jones R.B., and Shpall E.J. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 26 1 (2000) 109-111
283. Sastry J., Young S., and Shaw P.J. Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation. Bone Marrow Transplant 33 8 (2004) 867-868
284. Zavos G., Gazouli M., Psimenou E., Papaconstantinou I., Bokos J., Boletis J., Zografidis A., and Kostakis A. Polyomavirus BK infection in Greek renal transplant recipients. Transplant Proc 36 5 (2004) 1413-1414
285. Yocum D.E., Furst D.E., Bensen W.G., Burch F.X., Borton M.A., Mengle-Gaw L.J., Mengle-Gaw L.J., Schwartz B.D., Wisememandle W., Mekki Q.A., Tacrolimus R.A., and Study Group. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford) 43 8 (2004) 992-999
286. Milingou M., Antille C., Sorg O., Saurat J., and Lubbe J. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol 140 (2004) 1542-1543
287. Ehst B., and Warshaw E. Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin. Arch Dermatol 140 (2004) 1014-1015
288. Fontana I., Ginevri F., Basile G., Beatini M., Bertocchi M., Bonifazio L., Saltalamacchia L., Ghinolfi D., Santori G., Valente R., Perfumo F., and Valente U. Severe rhabdomyolysis and acute renal failure in a kidney transplant patient treated with tacrolimus and chimaeric CD25 monoclonal antibody. Transplant Proc 36 3 (2004) 711-712
289. Franco M., Blaimont A., Albano L., Bendini C., Cassuto E., and Jaeger P. Tacrolimus pain syndrome in renal transplant patients: report of two cases. Joint Bone Spine 71 2 (2004) 157-159
290. Orlandi V., Campieri C., Mosconi G., D'Arcangelo G.L., Feliciangeli G., Scolari M.P., and Stefoni S. Tacrolimus-associated myositis: a case report in a renal transplant patient. Transplant Proc 36 3 (2004) 708-710
291. Cure P., Pileggi A., Froud T., Norris P.M., Baidal D.A., Cornejo A., Hafiz M.M., Ponte G., Poggioli R., Yu J., Saab A., Selvaggi G., Ricordi C., and Alejandro R. Alterations of the female reproductive system in recipients of islet grafts. Transplantation 78 11 (2004) 1576-1581
292. Weiskittel P.D. West Nile virus infection in a renal transplant recipient. Nephrol Nurs J 31 3 (2004) 327-329
293. Lipshutz G.S., Flechner S.M., Govani M.V., and Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 4 12 (2004) 2132-2134
294. Wali R.K., Drachenberg C., Hirsch H.H., Papadimitriou J., Nahar A., Mohanlal V., Mohanlal V., Brisco M.A., Bartlett S.T., Weir M.R., and Ramos E. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 78 7 (2004) 1069-1073
295. Canet S., Garrigue V., Bismuth J., Chong G., Lesnik A., Taourel P., and Mourad G. La nocardiose est-elle plus fréquemment observée depuis l'introduction des nouveaux immunosuppresseurs en transplantation rénale? (Nocardiosis-is it frequently observed after the introduction of new immunosuppressive agents in renal transplantation?). Nephrologie 25 2 (2004) 43-48
296. Quinio D., Karam A., Leroy J.P., Moal M.C., Bourbigot B., Masure O., Sassolas B., and Le Flohic A.M. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol 42 2 (2004) 177-180
297. Bhatia M., Kher K., and Minniti C.P. Acute lymphoblastic leukemia in a child with nephrotic syndrome. Pediatr Nephrol 19 11 (2004) 1290-1293
298. Sato T., Nakajima M., Iguchi A., Kobayashi R., and Kobayashi K. Acute promyelocytic leukemia after living donor partial orthotopic liver transplantation. Rinsho Ketsueki 45 3 (2004) 233-237
299. Opelz G., and Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 2 (2004) 222-230
300. Kuypers D.R., Claes K., Evenepoel P., Maes B., and Vanrenterghem Y. The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. Drug Metab Dispos 32 12 (2004) 1421-1425
301. Kuypers D.R., Claes K., Evenepoel P., Maes B., Coosemans W., Pirenne J., and Vanrenterghem Y. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 43 11 (2004) 741-762
302. Schubert M., Venkataramanan R., Holt D.W., Shaw L.M., McGhee W., Reyes J., Webber S., and Sindhi R. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 4 5 (2004) 767-773
303. Tzakis A.G., Tryphonopoulos P., Kato T., Nishida S., Levi D.M., Madariaga J.R., Gaynor J.J., De Faria W., Regev A., Esquenazi V., Weppler D., Ruiz P., and Miller J. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 77 8 (2004) 1209-1214
304. Prescott Jr. W.A., Callahan B.L., and Park J.M. Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy 24 4 (2004) 532-537
305. Itagaki F., Homma M., Yuzawa K., Nishimura M., Naito S., Ueda N., Ohkohchi N., and Kohda Y. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol 56 8 (2004) 1055-1059
306. Takahashi K., Motohashi H., Yonezawa A., Okuda M., Ito N., Yamamoto S., Ogawa O., and Inui K. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother 38 5 (2004) 791-794
307. Christ B., Brockmeier D., Hauck E.W., and Kamali-Ernst S. Investigation on interaction between tacrolimus and sildenafil in kidney-transplanted patients with erectile dysfunction. Int J Clin Pharmacol Ther 42 3 (2004) 149-156
308. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43 10 (2004) 623-653
309. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. Drugs R D 5 6 (2004) 363-367
310. Raymond E., Alexandre J., Faivre S., Vera K., Materman E., Boni J., Leister C., Korth-Bradley J., Hanauske A., and Armand J.P. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 12 (2004) 2336-2347
311. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., Park Y., Liou S.H., Marshall B., Boni J.P., Dukart G., and Sherman M.L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 5 (2004) 909-918
312. Abetimus: Abetimus sodium, LJP 394. BioDrugs 17 3 (2003) 212-215
313. Wallace D.J., and Tumlin J.A. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 13 5 (2004) 323-327
314. Cardiel M.H. Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. Expert Opin Investig Drugs 14 1 (2005) 77-88
315. Thomas A., Pepper C., Hoy T., and Bentley P. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 45 5 (2004) 997-1008
316. Nezhat F., Wadler S., Muggia F., Mandeli J., Goldberg G., Rahaman J., Runowicz C., Murgo A.J., and Gardner G.J. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol 93 1 (2004) 144-148
317. Scheinfeld N., Rosenberg J.D., and Weinberg J.M. Levamisole in dermatology: a review. Am J Clin Dermatol 5 2 (2004) 97-104
318. Sanchez dM., Martinez-Augustin O., Gonzalez R., Ballester I., Nieto A., Galvez J., and Zarzuelo A. Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease. Biochem Pharmacol 68 12 (2004) 2317-2326
319. Davin J.C., and Merkus M.P. Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?. Pediatr Nephrol 20 1 (2005) 10-14
320. Martenson Jr. J.A., Willett C.G., Sargent D.J., Mailliard J.A., Donohue J.H., Gunderson L.L., Thomas Jr. C.R., Fisher B., Benson III A.B., Myerson R., and Goldberg R.M. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol 22 16 (2004) 3277-3283
321. Tsavaris N., Gennatas K., Kosmas C., Skopelitis H.M., Gouveris P., Dimitrakopoulos A., Zacharakis M., Kouraklis G., Vasiliou J., Felekouras E., Voros D., Zografos G., Balafouta M., Paraskevaidis M., Safioleas M., Fotiadis K., Papastratis G., Karatzas G., and Papalambros E. Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer. Oncol Rep 12 4 (2004) 927-932
322. Sukkar S.G., Schenone E., Foppiani L., and Nobile M.T. Experimental assessment of chemotherapy-induced early intestinal damage in colon cancer: the lactulose-mannitol permeability test. Tumori 90 5 (2004) 461-463
323. Sumegi V., Haszon I., Ivanyi B., Bereczki C., Papp F., and Turi S. Long-term effects of levamisole treatment in childhood nephrotic syndrome. Pediatr Nephrol 19 12 (2004) 1354-1360
324. Fu L.S., Shien C.Y., and Chi C.S. Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage. Nephron Clin Pract 97 4 (2004) c137-c141
325. Kazy Z., Puho E., and Czeizel A.E. Levamisole (Decaris) treatment during pregnancy. Reprod Toxicol 19 1 (2004) 3
326. Awadzi K., Edwards G., Opoku N.O., Ardrey A.E., Favager S., Addy E.T., Attah S.K., Yamuah L.K., and Quartey B.T. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann Trop Med Parasitol 98 6 (2004) 595-614
327. Schenkman E., and Lamm D.L. Superficial bladder cancer therapy. Scientific World Journal 4 Suppl 1 (2004) 387-399
328. Nagahashi S., Suzuki H., Nishiwaki M., Okuda K., Kurosawa Y., Terada S., Sugihara T., Andou K., and Hibi T. TS-1/CDDP/Lentinan combination chemotherapy for inoperable advanced gastric cancer. Gan To Kagaku Ryoho 31 12 (2004) 1999-2003
329. Piao B.K., Wang Y.X., Xie G.R., Mansmann U., Matthes H., Beuth J., and Lin H.S. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24 1 (2004) 303-309
330. Ishizuka Y., Tsukada H., and Gejyo F. Interference of (1 → 3)-beta-D-glucan administration in the measurement of plasma (1 → 3)-beta-D-glucan. Intern Med 43 2 (2004) 97-101
331. Ryoma Y., Moriya Y., Okamoto M., Kanaya I., Saito M., and Sato M. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res 24 5C (2004) 3295-3301
332. Blaszczynski M., Brazert K., Pietryga M., Persona-Sliwinska A., Brazert J., and Wender-Ozegowska E. Naczyniak limfatyczny-postepowanie i leczenie u noworodkow i niemolat-czesc druga (Lymphangioma-care and treatment in neonates and babies-Part two). Ginekol Pol 75 6 (2004) 431-438
333. Wheeler J.S., Morreau P., Mahadevan M., and Pease P. OK-432 and lymphatic malformations in children: the Starship Children's Hospital experience. ANZ J Surg 74 10 (2004) 855-858
334. Kim K.H., Sung M.W., Roh J.L., and Han M.H. Sclerotherapy for congenital lesions in the head and neck. Otolaryngol Head Neck Surg 131 3 (2004) 307-316
335. Sichel J.Y., Udassin R., Gozal D., Koplewitz B.Z., Dano I., and Eliashar R. OK-432 therapy for cervical lymphangioma. Laryngoscope 114 10 (2004) 1805-1809
336. Kishi K., Homma S., Sakamoto S., Kawabata M., Tsuboi E., Nakata K., and Yoshimura K. Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions. Eur Respir J 24 2 (2004) 263-266
337. Ikehara M., Oshita F., Suzuki R., Saitoh H., Yamada K., and Noda K. Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa. J Exp Ther Oncol 4 1 (2004) 79-83
338. Watanabe M., Nishida O., Kunii Y., Kodaira S., Takahashi T., Tominaga T., Hojyo K., Kato T., Niimoto M., Kunitomo K., Isomoto H., Ohashi Y., and Yasutomi M. Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur. Int J Clin Oncol 9 2 (2004) 98-106
339. Yamaguchi Y., Ohshita A., Kawabuchi Y., Hihara J., Miyahara E., Noma K., and Toge T. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment. Int J Oncol 24 4 (2004) 959-966
340. Goldstein A.L., and Badamchian M. Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther 4 4 (2004) 559-573
341. Philp D., Goldstein A.L., and Kleinman H.K. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev 125 2 (2004) 113-115
342. Jain A.K., Moore S.M., Yamaguchi K., Eling T.E., and Baek S.J. Selective nonsteroidal anti-inflammatory drugs induce thymosin beta-4 and alter actin cytoskeletal organization in human colorectal cancer cells. J Pharmacol Exp Ther 311 3 (2004) 885-891
343. Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., and Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432 7016 (2004) 466-472
344. Sjogren M.H. Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol 19 12 (2004) S69-S72
345. Liaw Y.F. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 19 12 (2004) S73-S75
346. Rustgi V. Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. J Gastroenterol Hepatol 19 12 (2004) S76-S78
347. Poo J.L., Sanchez-Avila F., Kershenobich D., Garcia-Samper X., Gongora J., and Uribe M. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. J Gastroenterol Hepatol 19 12 (2004) S79-S81
348. Andreone P., Gramenzi A., Cursaro C., Felline F., Loggi E., D'Errico A., Spinosa M., Lorenzini S., Biselli M., and Bernardi M. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J Viral Hepat 11 1 (2004) 69-73
349. Shuqun C., Mengchao W., Han C., Feng S., Jiahe Y., Wenming C., Peiun W., and Yuxiang Z. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology 51 59 (2004) 1445-1447
350. Cheng S.Q., Wu M.C., Chen H., Shen F., Yang J.H., Cong W.M., Zhao Y.X., and Wang P.J. Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 26 5 (2004) 305-307